Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Chronic Spontaneous Urticaria Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
There are a few different causes of urticaria. In some cases, it is a food allergy, and other causes are insect bites, medicines, and certain medications. In rare cases, urticaria may be caused by a viral infection. It is important to understand the causes of urticaria before determining what causes the symptoms. First, patients should avoid known allergens. Although antihistamines have been shown to improve a patient's symptoms, they may not work for everyone. Avoiding foods that are suspected of triggering urticaria is crucial. Some patients have no symptoms or may experience only intermittent attacks. For most people, urticaria has two main types - acute and chronic. Acute urticaria lasts for about six weeks and usually resolves on its own. In some cases, food allergies trigger acute urticaria, while others are the result of an inducible trigger. Sometimes, a viral infection or a vibrating tool can cause hives. In most cases, the trigger is food.
The global chronic spontaneous urticaria market focuses on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing incidence of urticaria in the world is expected to fuel the growth of the global chronic spontaneous urticaria market over the forecast period. For instance, according to the Medical Journals Sweden, around 1.1% of the global population suffers from urticarial. For chronic urticaria, hives persist for more than six weeks. Although the cause of chronic urticaria is usually unknown, there are several conditions that can trigger it. Cancer, thyroid disease, and hormonal imbalance are all common causes of chronic urticaria. In most cases, it is not necessary to seek medical attention for chronic urticaria because it goes away on its own. But the symptoms can interfere with daily activities. Increasing advanced treatment launches by key market players is estimated to enhance the growth of the global chronic spontaneous urticaria market.
Restraints:
Less awareness related to urticaria among individuals is expected to hinder the growth of the global chronic spontaneous urticaria market.
Regional Insights:
In regions, North America is expected to dominate the growth of the global chronic spontaneous urticaria market, owing to the increasing prevalence of urticarial in the region. For instance, according to the United States National Institutes of Health (NIH), more than 500,000 individuals in the United States suffer from urticaria. Moreover, the Asia Pacific is estimated to witness significant growth in the global chronic spontaneous urticaria market owing to the increasing expansion of health research and development in the region. The gradual incidence of this disease in the region is assessed to drive the market growth.
Competitive Section:
Key players operating in the global chronic spontaneous urticaria market include Johnson & Johnson Private Limited, AstraZeneca, LEO Pharma A/S, Lupin, Allergan, Eli Lilly and Company, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries, Ltd., F. Hoffmann La Roche Ltd., Cipla Inc., AbbVie, Inc., WOCKHARDT, Hikma Pharmaceuticals, PLC, Aurobindo Pharma, Merck & Co., Inc., Bayer AG, GlaxoSmithKline, PLC, Sanofi, and Mylan N. V.
Chronic Spontaneous Urticaria Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The Chronic Spontaneous Urticaria Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the Chronic Spontaneous Urticaria Market.
Companies profiled in the Chronic Spontaneous Urticaria Market report include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co. Inc. (US)
- Allergan (Ireland)
- Aurobindo Pharma (Hyderabad)
- Lupin (Mumbai)
- Hikma Pharmaceuticals Plc (UK)
- LEO Pharma A/S (Denmark)
- WOCKHARDT (Mumbai)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the Chronic Spontaneous Urticaria Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
- Medication
- Phototherapy
- Others
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
- Hospitals
- Specialty Clinics
- Homecare
- Others
Key Benefits for Stakeholders:
- The study represents a quantitative analysis of the present Chronic Spontaneous Urticaria Market trends, estimations, and dynamics of the market size from 2022 to 2028 to determine the most promising opportunities.
- Porter's five forces study emphasizes the importance of buyers and suppliers in assisting stakeholders to make profitable business decisions and expand their supplier-buyer network.
- In-depth analysis, as well as market size and segmentation, help you identify current Chronic Spontaneous Urticaria market opportunities.
- The largest countries in each region are mapped according to their revenue contribution to the market.
- The Chronic Spontaneous Urticaria Market research report gives a thorough analysis of the current status of the Chronic Spontaneous Urticaria Market's major players.
Reasons to Purchase Chronic Spontaneous Urticaria Market Report:
- Both current and future prospects for the Chronic Spontaneous Urticaria Market in developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis.
- During the forecast period, major regions are expected to see the most rapid increase.
- Identify the most recent advancements, Chronic Spontaneous Urticaria Market shares, and top market players' strategies.
Research Methodology:
To estimate and validate the size of the Chronic Spontaneous Urticaria Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
